Rasburicase Side Effects
Some side effects of rasburicase may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to rasburicase: intravenous powder for solution
Along with its needed effects, rasburicase may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking rasburicase:More common
- Cracked lips
- difficulty with swallowing
- sores, ulcers, or white spots on the lips, tongue, or inside the mouth
- Abdominal or stomach pain
- black or red, tarry, stools
- bleeding gums
- bluish color of the fingernails, lips, skin, palms, or nail beds
- changes in skin color
- changes in vision
- chest pain or discomfort
- convulsions (seizures)
- coughing that sometimes produces a pink, frothy sputum
- coughing up blood
- decreased urination
- dilated neck veins
- dry mouth
- fast, slow, or irregular heartbeat
- increased menstrual flow or vaginal bleeding
- increased sweating
- increased thirst
- itching, pain, redness, swelling, tenderness, or warmth on the skin
- lower back or side pain
- muscle twitching
- no blood pressure or pulse
- pain or discomfort in the arms, jaw, back, or neck
- pain, tenderness, or swelling of the foot or leg
- painful or difficult urination
- pains in the chest, groin, or legs, especially calves of the legs
- pale skin
- prolonged bleeding from cuts
- red or dark brown urine
- severe constipation
- severe headaches of sudden onset
- shortness of breath
- skin rash
- sore throat
- stopping of heart
- sudden loss of coordination
- sudden onset of shortness of breath for no apparent reason
- sudden onset of slurred speech
- sunken eyes
- swelling of the face, fingers, feet, or lower legs
- swollen glands
- temporary blindness
- tightness in the chest
- troubled breathing
- unexplained or unusual bleeding or bruising
- unusual tiredness or weakness
- weight gain
- wrinkled skin
- Back pain
- itching, puffiness, or swelling of the eyelids or around the eyes, face, lips, or tongue
- yellow eyes or skin
Some side effects of rasburicase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- feeling of warmth
- feeling unusually cold
- redness of the face, neck, arms, and occasionally, upper chest
For Healthcare Professionals
Applies to rasburicase: intravenous powder for injection
Immunologic side effects associated with the use of rasburicase in healthy volunteers have included reports of development of binding antibodies to rasburicase and neutralizing antibodies.
Metabolic side effects including at least one case of hypocalcemia have been reported.
Gastrointestinal (GI) side effects have been reported the most frequently. These have included vomiting, nausea, abdominal pain, constipation, and diarrhea. Ileus and intestinal obstruction have been reported in less than 1% patients included in studies (n = 703). At least one case of GI hemorrhage has also been reported.
Respiratory side effects have included respiratory distress, pulmonary edema, pulmonary hypertension, and pneumonia.
Cardiovascular side effects have been reported rarely. Less than 1% (n = 703) of patients have reported arrhythmia, cardiac failure, cardiac arrest, chest pain, and myocardial infarction.
Renal side effects have been reported rarely. Acute renal failure has been reported in less than 1% of patients included in the studies (n = 703).
Ocular side effects have included reports of retinal hemorrhage.
A 50-year-old male who was admitted to the hospital for new onset seizure, diabetic ketoacidosis, respiratory failure, and acute renal failure experienced hemolytic anemia and methemoglobinemia coincident with rasburicase therapy. He was given one dose of intravenous rasburicase 22.5 mg for acute renal failure secondary to hyperuricemia. Routine arterial blood gas analysis performed after rasburicase was given revealed elevated methemoglobin concentrations, which peaked at 14.7%. Hemolytic anemia developed as evidenced by a reduction in blood hemoglobin from 14.8 to 5.3 g/dL. The patient made a complete recovery following aggressive fluid therapy, blood transfusions, and respiratory support.
Hematologic side effects have included reports of neutropenia (2%), neutropenia with fever (4%), thrombosis, thrombophlebitis, and pancytopenia. At least two cases of methemoglobinemia have also been reported, in addition to a case of hemolytic anemia.
Dermatologic side effects have included reports of rash (13%) and cellulitis (1% or less).
Nervous system side effects have included headache (1.8%), cerebrovascular disorder, and convulsions.
Musculoskeletal side effects including at least one case of arthralgia and one case of gout have been reported.
Hypersensitivity side effects including allergic reactions have been reported in 0.7% of patients.
Hepatic side effects including increased serum glutamic pyruvate transaminase have been reported. At least 3 cases of increased liver enzymes have also been reported.
Other side effects including fever (1.4% to 5%) and rigors (1.1%) have been reported. A neonate with glucose-6-phosphate dehydrogenase (G6PD) deficiency died following a single dose of rasburicase.
A case report describes the lethal effect of a single dose of rasburicase in a preterm newborn infant with glucose-6-phosphate dehydrogenase (G6PD) deficiency who was treated for an increase in uric acid levels. It is suggested that G6PD testing be considered before rasburicase use.
More rasburicase resources
- rasburicase Concise Consumer Information (Cerner Multum)
- rasburicase MedFacts Consumer Leaflet (Wolters Kluwer)
- rasburicase Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
- Rasburicase Professional Patient Advice (Wolters Kluwer)
- Rasburicase Monograph (AHFS DI)
- Elitek Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.